Article
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia.
International journal of cancer - 15 Aug 2018
Baldoni Stefano, Del Papa Beatrice, Dorillo Erica, Aureli Patrizia, De Falco Filomena, Rompietti Chiara, Sorcini Daniele, Varasano Emanuela, Cecchini Debora, Zei Tiziana, Di Tommaso Ambra, Rosati Emanuela, Alexe Gabriela, Roti Giovanni, Stegmaier Kimberly, Di Ianni Mauro, Falzetti Franca, Sportoletti Paolo
Abstract excerpt
Dysregulated NOTCH1 signaling, by either gene mutations or microenvironment interactions, has been increasingly linked to chronic lymphocytic leukemia (CLL). Thus, inhibiting NOTCH1 activity represents a potential therapeutic opportunity for this disease. Using gene expression-based screening, we identified the calcium channel modulator bepridil as a new NOTCH1 pathway inhibitor. In primary CLL cells, bepridil...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.